Uncategorized

RC Capital, Mutual Capital Partners and Western Alliance Bank, reinforce long-term confidence in Catalyst’s vision and leadership; Dr. Theodore Blaine joins Catalyst board of directors  NAPLES, Fla., Oct. 22, 2025 – Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the…

The new system designed to improve reverse shoulder arthroplasty for proximal humeral fractures includes patented technology that helps reduce surgical complexity and drive clinical confidence NAPLES, Fla., August 12, 2025 – Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the…

Mid-term results for Catalyst CSR™ shoulder system include outcomes for 200+ shoulders and show exceptionally high patient satisfaction scores in a wide age range of patients NAPLES, Fla., June 4, 2025 – Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in…

NAPLES, Fla., April 2, 2025 – Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, announced the appointment of Dr. Miguel Ramirez as chief medical officer (CMO), effective immediately. Dr. Ramirez succeeds Dr. Steven Goldberg, Catalyst’s founder, who…

NAPLES, Fla., October 22, 2024 – Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, announced that it has appointed Amy Ables, PhD, as chief commercial officer (CCO) of the organization, effective immediately. Dr. Ables joined Catalyst in…

NAPLES, Fla., - Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, announces it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and the first surgeries have been successfully performed for the Catalyst Fracture…